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Most patients with pulmonary arterial hypertension
succumb to their disease in the ICU; however, limited
evidence-based information exists to guide treatment
in those that present with advanced right ventricular
failure. Critical care physicians should be aware of
the complexities of the treatment of patients with
pulmonary arterial hypertension and should develop a
strategy for their care. Current management is based
on the pathophysiology of the disease and involves a
multidisciplinary team supported by institutional polices
directed at optimizing patient safety.[5] and pulmonary edema in patients with pulmonaryThe article by Muzevich and colleagues addresses im-
portant issues surrounding medication therapy in pa-
tients with pulmonary arterial hypertension (PAH) that
present to the ICU [1]. This review is very relevant to
the critical care physician since most patients with PAH
die from their underlying disease in the ICU while
receiving PAH-specific therapy [2]. Fortunately, there
are now nine pharmacological agents with US Food and
Drug Administration-approved labeling for use in PAH,
two of which were approved in 2013. These medications
have marked pharmacological differences, which poses a
particular challenge in critical care patients. Muzevich and
colleagues have summarized the literature and presented
their experience in the management of PAH-specific therap-
ies in ICU patients [1]. We have selected particularly chal-
lenging areas to emphasize important points, present an
alternative approach and identify areas for future research.
Of particular relevance is the lack of data on the com-
parative effectiveness of different vasodilator therapies
either used alone or in combination [3]. Further research* Correspondence: tonella@ccf.org
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for 12 months following its publication. After th
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medium, provided the original work is properly
(http://creativecommons.org/publicdomain/zeroin this area is certainly needed. Parenteral prostacyclin
analogs (that is, epoprostenol and treprostinil) are rec-
ommended for patients with PAH who present with
right heart failure or progression of their disease [4].
However, the best treatment approach is unclear for pa-
tients with PAH and worsening right heart failure while
already receiving a parenteral prostacyclin analog. In these
patients, we continue all PAH-specific therapies unless
there is a suspicion that the patient’s presentation could
be a side effect of any of these medications (particularly
in cases of recent dose changes or initiation of therapy).
Two noteworthy side effects are lower extremity edema
in patients treated with endothelin receptor antagonists
veno-occlusive disease treated with parenteral prostacyclin
analogs [6]. Pulmonary veno-occlusive disease is a rare
form of pulmonary hypertension that is particularly chal-
lenging to diagnose and is characterized by narrowing of
the small pulmonary veins.
In PAH patients with worsening right heart failure, we
increase the dose of the prostacyclin analog and, if they
are not already on this treatment, we start oral sildenafil
(initial dose 10 mg every 8 hours with uptitration as tol-
erated). Sildenafil, a well-tolerated phosphodiesterase-5
inhibitor, is the preferred treatment due to its rapid
onset of action and a relatively short plasma half-life
(approximately 4 hours). Conversely, endothelin receptor
antagonists require weeks to demonstrate noticeable
pharmacodynamic effects.
If the cardiac index is low, we add dobutamine or milri-
none since these inotropic agents have vasodilatory prop-
erties, thereby increasing right ventricular function and
reducing pulmonary vascular resistance [7]. In patients
receiving treprostinil subcutaneously we switch this pros-
tacyclin analog to intravenous administration, given that
the absorption of treprostinil via the subcutaneous route
might not be reliable in this particular situation [8]. We
use aerosolized epoprostenol in severely ill patients who
do not tolerate rapid titration of intravenous prostacyclinntral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
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to-left shunt. Of note, we utilize the epoprostenol formu-
lation that contains glycine (Flolan®; GlaxoSmithKline,
Research Triangle Park, NC, USA) instead of the for-
mulation containing arginine (Veletri®; Actelion, South
San Francisco, CA, USA) because of the more extensive
safety data, particularly in postoperative patients [9]. We
have noted many technical challenges with the admi-
nistration of aerosolized epoprostenol (such as cannula
displacement and interruptions in the delivery system)
leading to unexpected hemodynamic decompensation
[10,11]. Extensive staff training and procedures to ensure
safe use are therefore of the outmost importance when
using aerosolized epoprostenol.
Catheter-related bloodstream infection is not uncommon
in patients with PAH receiving a parenteral prostacyclin,
with an incidence of approximately 0.3 to 0.5 cases per
1,000 treatment-days [12,13]. In our institution, pa-
tients presenting with a catheter-related bloodstream
infection have a peripheral intravenous line placed and
the tunneled catheter is rapidly removed. Our nurses
are trained to obtain a reliable peripheral intravenous
line and to check its status on a regular basis. For patients
in whom a reliable peripheral venous access cannot be
established, a peripheral inserted central catheter is placed
for parenteral prostacyclin administration. Once clinical
defervescence occurs and blood cultures remain negative
for ≥2 days (other centers recommend ≥4 days [14]),
a new tunneled catheter is inserted. This approach
has allowed us to decrease the hospital length of stay.
The Pulmonary Hypertension Association has made
important recommendations to prevent central venous
catheter infections in PAH receiving parenteral pros-
tacyclin analogs [14]. These recommendations include
the use of a cuffed and tunneled catheter with the mini-
mum number of lumens (ideally one) and a closed hub
system.
Given that the treatments for patients with PAH are
complex and mistakes are possible, it is important to
emphasize the need for a multidisciplinary team ap-
proach that includes critical care physicians, pulmonary
hypertension experts, pharmacists, experienced nurses
and social workers. In addition, there should be institu-
tionally tailored protocols for the use of PAH therapies
to prevent errors during the prescription, preparation or
administration of these agents. These protocols could be
accomplished by the use of order templates and exten-
sive pharmacy and nursing checks.Abbreviation
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